Veit Scheble

Author PubWeight™ 16.91^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.	Nat Genet	2009	7.48
2	Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma.	BMC Cancer	2011	1.74
3	Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.	Mod Pathol	2010	1.55
4	SOX2 amplification is a common event in squamous cell carcinomas of different organ sites.	Hum Pathol	2011	1.40
5	Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.	Chest	2012	1.15
6	SOX2 expression and prognostic significance in ovarian carcinoma.	Int J Gynecol Pathol	2013	0.93
7	Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.	Eur J Haematol	2008	0.91
8	Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma.	Lung Cancer	2011	0.89
9	Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a clonal event during prostate cancer progression.	Hum Pathol	2012	0.83
10	Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.	J Pathol	2013	0.79